Intellia Therapeutics (NTLA) News Today

$21.53
-0.30 (-1.37%)
(As of 04/23/2024 ET)
SourceHeadline
MarketBeat logoIntellia Therapeutics' (NTLA) "Neutral" Rating Reaffirmed at Wedbush
americanbankingnews.com - April 24 at 4:48 AM
marketbeat.com logoIntellia Therapeutics' (NTLA) Neutral Rating Reaffirmed at Wedbush
marketbeat.com - April 23 at 1:49 PM
marketbeat.com logoFederated Hermes Inc. Increases Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
marketbeat.com - April 20 at 6:58 AM
marketbeat.com logoSumitomo Mitsui Trust Holdings Inc. Sells 41,733 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)
marketbeat.com - April 17 at 6:09 AM
marketbeat.com logoIntellia Therapeutics (NASDAQ:NTLA) Reaches New 12-Month Low at $22.51
marketbeat.com - April 15 at 5:31 PM
marketbeat.com logoMirae Asset Global Investments Co. Ltd. Sells 100,885 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)
marketbeat.com - April 15 at 5:17 AM
marketbeat.com logoCapital Advisors Inc. OK Acquires 73,379 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)
marketbeat.com - April 13 at 5:00 PM
fool.com logoCathie Wood Goes Bargain Hunting. 2 Stocks She Bought This Week.
fool.com - April 12 at 4:50 AM
fool.com logoBull Market and Beyond: 3 Stocks Just Waiting to Soar
fool.com - April 9 at 4:50 AM
marketbeat.com logoIntellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Rating of "Moderate Buy" by Analysts
marketbeat.com - April 5 at 6:36 AM
marketbeat.com logoIntellia Therapeutics (NASDAQ:NTLA) Shares Down 7.1%
marketbeat.com - April 2 at 5:45 PM
benzinga.com logoSmart Money Is Betting Big In NTLA Options
benzinga.com - March 28 at 8:07 PM
marketbeat.com logoARK Investment Management LLC Grows Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
marketbeat.com - March 28 at 6:39 AM
fool.com logoBetter Cathie Wood Stock: Moderna vs. Intellia
fool.com - March 28 at 5:55 AM
marketwatch.com logoIntellia Therapeutics Ends Co-Development Agreement With Regeneron
marketwatch.com - March 22 at 6:12 PM
msn.com logoIntellia opts out of hemophilia pact with Regeneron
msn.com - March 22 at 6:12 PM
investorplace.com logoHot Stocks: The 3 Best Opportunities for Investing in Biotech
investorplace.com - March 21 at 5:29 PM
investorplace.com logo3 Stocks That Could Be the Next Big Thing in Gene Editing
investorplace.com - March 21 at 4:19 PM
investing.com logoIntellia begins phase 3 trial for CRISPR therapy NTLA-2001
investing.com - March 20 at 5:25 PM
marketbeat.com logoIntellia Therapeutics, Inc. (NASDAQ:NTLA) Stock Holdings Increased by Wellington Management Group LLP
marketbeat.com - March 19 at 4:53 AM
globenewswire.com logoIntellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy
globenewswire.com - March 18 at 7:30 AM
marketbeat.com logoIntellia Therapeutics (NASDAQ:NTLA) Trading Down 3.6%
marketbeat.com - March 12 at 1:24 PM
marketbeat.com logoIntellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Recommendation of "Moderate Buy" by Analysts
marketbeat.com - March 11 at 6:17 AM
fool.com logoIs Intellia Therapeutics Stock a Buy Now?
fool.com - March 9 at 9:45 AM
fool.com logoIntellia Therapeutics Stock Has 119% Upside, According to 1 Wall Street Analyst
fool.com - March 6 at 10:35 AM
marketbeat.com logoEventide Asset Management LLC Sells 120,557 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)
marketbeat.com - March 1 at 9:33 AM
seekingalpha.com logoIntellia Therapeutics Is On The Move
seekingalpha.com - February 29 at 12:35 PM
marketbeat.com logoFY2024 Earnings Forecast for Intellia Therapeutics, Inc. (NASDAQ:NTLA) Issued By Cantor Fitzgerald
marketbeat.com - February 29 at 8:41 AM
fool.com logoA Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right Now
fool.com - February 29 at 7:17 AM
fool.com logoCathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
fool.com - February 27 at 11:55 AM
markets.businessinsider.com logoAnalysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Intellia Therapeutics (NTLA) and Cue Biopharma (CUE)
markets.businessinsider.com - February 26 at 3:22 PM
markets.businessinsider.com logoHold Rating for Intellia Therapeutics Amid Clinical Trials and Competitive Dynamics
markets.businessinsider.com - February 26 at 10:22 AM
markets.businessinsider.com logoBuy Rating Affirmed for Intellia Therapeutics on Strong Clinical Execution and Financial Health
markets.businessinsider.com - February 26 at 10:22 AM
marketbeat.com logoIs CRISPR Therapeutics the NVIDIA of gene editing? (NTLA)
marketbeat.com - February 26 at 7:02 AM
finance.yahoo.com logoIntellia Therapeutics, Inc. (NASDAQ:NTLA) Analysts Are Cutting Their Estimates: Here's What You Need To Know
finance.yahoo.com - February 25 at 8:36 AM
realmoney.thestreet.com logoIntellia Therapeutics just downgraded at Goldman Sachs, here's why
realmoney.thestreet.com - February 24 at 9:33 AM
msn.com logoGoldman Sachs Downgrades Intellia Therapeutics (NTLA)
msn.com - February 24 at 9:33 AM
marketbeat.com logoCharles Schwab Investment Management Inc. Has $21.54 Million Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
marketbeat.com - February 24 at 4:25 AM
marketbeat.com logoIntellia Therapeutics (NASDAQ:NTLA) Shares Down 5.8%
marketbeat.com - February 23 at 2:56 PM
markets.businessinsider.com logoStrong Buy Rating for Intellia Therapeutics Amid Positive Trial Updates and Robust Financial Standing
markets.businessinsider.com - February 23 at 2:23 PM
finance.yahoo.com logoIntellia Therapeutics, Inc. (NASDAQ:NTLA) Q4 2023 Earnings Call Transcript
finance.yahoo.com - February 23 at 2:23 PM
marketbeat.com logoIntellia Therapeutics (NASDAQ:NTLA) Issues Earnings Results, Beats Expectations By $0.01 EPS
marketbeat.com - February 23 at 12:53 PM
marketbeat.com logoIntellia Therapeutics (NASDAQ:NTLA) Given New $73.00 Price Target at Canaccord Genuity Group
marketbeat.com - February 23 at 10:17 AM
marketbeat.com logoIntellia Therapeutics (NASDAQ:NTLA) Lowered to "Neutral" at The Goldman Sachs Group
marketbeat.com - February 23 at 9:43 AM
markets.businessinsider.com logoIntellia Therapeutics: Hold Rating Maintained Amid Fair Valuation and Anticipated Clinical Milestones
markets.businessinsider.com - February 23 at 8:45 AM
marketbeat.com logoIntellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Sold by Federated Hermes Inc.
marketbeat.com - February 23 at 8:38 AM
finance.yahoo.com logoQ4 2023 Intellia Therapeutics Inc Earnings Call
finance.yahoo.com - February 22 at 11:16 PM
finance.yahoo.com logoIntellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress
finance.yahoo.com - February 22 at 8:14 AM
globenewswire.com logoIntellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress
globenewswire.com - February 22 at 7:30 AM
benzinga.com logoA Preview Of Intellia Therapeutics's Earnings
benzinga.com - February 21 at 3:43 PM
Get Intellia Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter.

Bitcoin Rockets To Record High But Buy THIS Instead (Ad)

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

NTLA Media Mentions By Week

NTLA Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

NTLA
News Sentiment

0.80

0.44

Average
Medical
News Sentiment

NTLA News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

NTLA Articles
This Week

4

4

NTLA Articles
Average Week

Get Intellia Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:NTLA) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners